Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
- PMID: 28685247
- DOI: 10.1007/s12016-017-8622-7
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Abstract
Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.
Keywords: Immunopathology; Pathophysiology; Review; Therapy; Vitiligo.
Similar articles
-
New insights into immune mechanisms of vitiligo.G Ital Dermatol Venereol. 2016 Feb;151(1):44-54. Epub 2015 Oct 29. G Ital Dermatol Venereol. 2016. PMID: 26512930 Review.
-
The enigma and challenges of vitiligo pathophysiology and treatment.Pigment Cell Melanoma Res. 2020 Nov;33(6):778-787. doi: 10.1111/pcmr.12878. Epub 2020 Apr 12. Pigment Cell Melanoma Res. 2020. PMID: 32198977 Review.
-
Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.Clin Rev Allergy Immunol. 2021 Dec;61(3):299-323. doi: 10.1007/s12016-021-08868-z. Epub 2021 Jul 20. Clin Rev Allergy Immunol. 2021. PMID: 34283349 Review.
-
Vitiligo.Nat Rev Dis Primers. 2015 Jun 4;1:15011. doi: 10.1038/nrdp.2015.11. Nat Rev Dis Primers. 2015. PMID: 27189851 Review.
-
Clinical Features of Vitiligo and Social Impact on Quality of Life.Dermatol Pract Concept. 2023 Dec 1;13(4S2):e2023312S. doi: 10.5826/dpc.1304S2a312S. Dermatol Pract Concept. 2023. PMID: 38241394 Free PMC article. Review.
Cited by
-
Clinical efficacy of CO2 fractional laser combined with compound betamethasone in treating vitiligo and its impact on inflammatory factors.Front Med (Lausanne). 2024 Jul 10;11:1408409. doi: 10.3389/fmed.2024.1408409. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39050532 Free PMC article.
-
T cell pathology in skin inflammation.Semin Immunopathol. 2019 May;41(3):359-377. doi: 10.1007/s00281-019-00742-7. Epub 2019 Apr 26. Semin Immunopathol. 2019. PMID: 31028434 Free PMC article. Review.
-
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?Front Immunol. 2024 May 29;15:1405215. doi: 10.3389/fimmu.2024.1405215. eCollection 2024. Front Immunol. 2024. PMID: 38868763 Free PMC article. Review.
-
Consensus on the treatment of vitiligo - Brazilian Society of Dermatology.An Bras Dermatol. 2020 Nov-Dec;95 Suppl 1(Suppl 1):70-82. doi: 10.1016/j.abd.2020.05.007. Epub 2020 Oct 10. An Bras Dermatol. 2020. PMID: 33153826 Free PMC article.
-
Updates and new medical treatments for vitiligo (Review).Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. Exp Ther Med. 2021. PMID: 34093753 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical